Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionCapital International Sarl
Latest Disclosed Ownership208,882 shares
Latest Disclosed Value $ 93,274,168
Capital International Sarl reports 7.98% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 13, 2026 - Capital International Sarl filed a 13F-HR form disclosing ownership of 208,882 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $93,274,168 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 193,438 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 7.98% during the quarter. The current value of the position is $93,334,744 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 208,882 15,444 7.98 93,274 6.36 1.5271
2026-02-11 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 193,438 -32,296 -14.31 87,697 -0.80 1.4082
2025-11-13 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 225,734 2,345 1.05 88,406 -11.11 1.5274
2025-08-13 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 223,389 37,218 19.99 99,453 10.19 1.9104
2025-05-12 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 186,171 17,579 10.43 90,259 32.95 2.0438
2025-02-13 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 168,592 25,544 17.86 67,892 2.05 1.5670
2024-11-13 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 143,048 18,968 15.29 66,529 14.39 1.7093
2024-08-13 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 124,080 7,602 6.53 58,159 19.45 1.7757
2024-05-14 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 116,478 22,891 24.46 48,689 27.86 1.6142
2024-02-13 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 93,587 14,113 17.76 38,080 37.79 1.4263
2023-11-13 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 79,474 5,799 7.87 27,636 6.60 1.2645
2023-08-11 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 73,675 15,253 26.11 25,927 40.85 1.1633
2023-05-15 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 58,422 7,652 15.07 18,407 25.55 0.9292
2023-02-14 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 50,770 3,057 6.41 14,661 6.12 1.0320
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 47,713 4,461 10.31 13,815 13.35 1.1156
2022-08-15 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 43,252 1,225 2.91 12,188 11.12 0.9769
2022-05-19 2022-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 42,027 -4,528 -9.73 10,968 7.29 0.5439
2022-05-16 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 42,027 -4,528 10,968 0.5508
2022-02-14 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 46,555 33,939 269.02 10,223 346.81 0.4876
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 12,616 -2,214 -14.93 2,288 -23.48 0.2023
2021-08-16 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 14,830 341 2.35 2,990 -3.98 0.2582
2021-05-14 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 14,489 374 2.65 3,114 -6.65 0.2971
2021-02-16 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 14,115 393 2.86 3,336 -10.66 0.3486
2020-11-16 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 13,722 536 4.06 3,734 -2.46 0.4582
2020-08-14 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 13,186 2,424 22.52 3,828 49.47 0.5091
2020-05-15 2020-03-31 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 10,762 3,188 42.09 2,561 54.46 0.4662
2020-02-18 2019-12-31 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 7,574 7,574 1,658 0.2572
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.